V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 320003604 | 320002186 | 1.64 | 78.5 | Palliative (P) | 2016-08-04 | 2016-08-15 | Cisplatin + Gemcitabine (D 1 & 8) | 2 | N | 320023362 | CISPLATIN + GEMCITABINE |
| 320003605 | 320002187 | 1.8 | 86.3 | null | 2013-06-14 | 2013-06-18 | CARBOPLATIN + RT | N | N | 320023369 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320003606 | 320005044 | 1.76 | 93 | Neo-adjuvant (N) | 2015-01-05 | 2015-01-05 | CISPLATIN + DOCETAXEL + FLUOROURACIL | N | N | 320023373 | CETUXIMAB + CISPLATIN + FU |
| 320003607 | 320002188 | 1.65 | 0 | Palliative (P) | 2014-06-30 | 2014-06-30 | TEMOZOLOMIDE | 02 | N | 320023379 | DOCETAXEL |
| 320003608 | 320002189 | 1.5 | 72.8 | Neo-adjuvant (N) | 2013-06-08 | 2013-06-09 | BCG Intravesical | N | N | 320023380 | CISPLATIN + GEMCITABINE |
| 320003609 | 320002190 | null | 107.7 | Neo-adjuvant (N) | 2017-05-08 | 2017-05-22 | Trial Unspecified | N | Y | 320023388 | CISPLATIN + FLUOROURACIL + RT |
| 320003610 | 320002191 | 0 | 57.9 | Disease modification (D) | null | 2016-10-24 | Bevacizumab+Carbo+Pacliaxel | null | null | 320023391 | CARBOPLATIN + ETOPOSIDE |
| 320003611 | 320002192 | 1.58 | 74.4 | Adjuvant (A) | 2013-08-01 | 2013-08-08 | Cisplatin + Gemcitabine (D 1 & 8) | N | N | 320023393 | EC + PACLITAXEL |
| 320003612 | 320005045 | null | null | Palliative (P) | null | 2016-06-04 | Bevacizumab+Carbo+Pacliaxel | null | null | 320023395 | BEVACIZUMAB |
| 320003613 | 320002193 | 1.56 | null | Disease modification (D) | null | 2015-06-13 | Cisplatin + Docetaxel +Fluorouracil | null | null | 320023403 | CETUXIMAB + CISPLATIN + FU |
| 320003614 | 320002194 | 1.77 | 0 | Curative (C) | 2017-05-04 | 2017-05-14 | CETUXIMAB + RT | N | null | 320023405 | CARBOPLATIN + RT |
| 320003615 | 320002195 | 1.71 | 59.5 | Palliative (P) | 2016-10-26 | 2016-11-10 | Cisplatin + Docetaxel +Fluorouracil | N | N | 320023420 | CETUXIMAB |
| 320003616 | 320002195 | 1.73 | 0 | Palliative (P) | 2016-05-10 | 2016-05-11 | Carboplatin+Fluorouracil 4 or 5 day | 02 | null | 320023420 | CARBO + FLUOROURACIL |
| 320003617 | 320002196 | 1.73 | 81 | Curative (C) | null | 2015-10-02 | Cisplatin + Etoposide (3 day) | N | Y | 320023443 | OCTREOTIDE |
| 320003618 | 320002197 | 1.52 | 51 | Curative (C) | 2018-08-23 | 2018-08-23 | Carboplatin+Fluorouracil 4 or 5 day | N | null | 320023448 | OXALIPLATIN + MDG |
| 320003619 | 320002197 | 1.6 | 0 | Palliative (P) | 2015-10-21 | 2015-10-21 | Cisplatin + Fluorouracil + RT 5day | 02 | N | 320023448 | EOX |
| 320003620 | 320002198 | null | 60 | Palliative (P) | null | 2014-05-15 | STS Rhabdo RMS 2005 Vin Cyclo | null | null | 320023472 | CARBOPLATIN + LIPOSOMAL DOX |
| 320003621 | 320002199 | 1.82 | 102.4 | Palliative (P) | null | 2016-05-30 | ETOPOSIDE + IFOSFAMIDE | N | N | 320023474 | CISPLATIN + FLUOROURACIL + RT |
| 320003622 | 320002200 | 1.66 | 40 | null | 2016-09-15 | 2016-09-30 | Docetaxel 75mg/m2 (21 day) | N | N | 320023477 | ICON8B TRIAL |
| 320003623 | 320002200 | 0.01 | 66 | Neo-adjuvant (N) | 2016-07-01 | 2017-10-24 | Cisplatin + Vinorelbine (IV) | N | N | 320023477 | TIP |
| 320003624 | 320002200 | null | null | Not known (9) | null | 2014-08-23 | Oxaliplatin + Modified de Gramont | null | null | 320023477 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320003625 | 320002201 | 1.72 | 59.4 | Neo-adjuvant (N) | 2016-09-17 | 2016-10-05 | Cetuximab 7 day (Cycle 1) | N | null | 320023487 | CARBOPLATIN + DOCETAXEL + FLUOROURACIL |
| 320003626 | 320002202 | null | null | Palliative (P) | null | 2015-03-28 | CAP | null | null | 320023494 | CETUXIMAB |
| 320003627 | 320002203 | 1.66 | 103 | Adjuvant (A) | 2017-05-26 | 2017-06-06 | Cisplatin + Gemcitabine (D 1 & 8) | 2 | N | 320023496 | CETUXIMAB + RT |
| 320003628 | 320002203 | 1.82 | 65.1 | Palliative (P) | 2016-02-25 | 2016-03-02 | CISPLATIN + DOCETAXEL + FLUOROURACIL | Y | N | 320023496 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN |
| 320003629 | 320006361 | 1.64 | 35.45 | Adjuvant (A) | 2014-01-20 | 2014-01-27 | PACLITAXEL | N | Y | 320023510 | CISPLATIN + GEMCITABINE |
| 320003630 | 320006361 | 1.79 | 75.8 | Palliative (P) | 2018-02-09 | 2018-02-18 | CARBOPLATIN + ETOPOSIDE | N | N | 320023510 | CISPLATIN + GEMCITABINE |
| 320003631 | 320006361 | 1.71 | 112 | Curative (C) | 2018-01-15 | 2018-01-26 | CISPLATIN + DOCETAXEL + FLUOROURACIL | 02 | N | 320023510 | CARBOPLATIN + ETOPOSIDE |
| 320003632 | 320002204 | 1.65 | 55.3 | Neo-adjuvant (N) | 2016-05-06 | 2017-05-27 | Cisplatin + Docetaxel +Fluorouracil | 02 | N | 320023523 | OCTREOTIDE |
| 320003633 | 320002205 | 1.8 | 82.2 | Adjuvant (A) | 2016-03-02 | 2016-03-27 | Enzalutamide | 2 | Y | 320023527 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320003634 | 320002206 | 1.62 | 73.9 | Palliative (P) | 2015-10-17 | 2015-11-07 | EOX | N | N | 320023537 | CETUXIMAB + CISPLATIN + FU |
| 320003635 | 320002207 | 1.56 | null | Neo-adjuvant (N) | 2017-03-12 | 2017-03-12 | POUT TRIAL | N | N | 320023538 | CARBOPLATIN + RT |
| 320003636 | 320002207 | 1.73 | null | Palliative (P) | 2015-01-13 | 2015-01-13 | Cetuximab 7 day (Cycle 1) | N | N | 320023538 | CISPLATIN + ETOPOSIDE |
| 320003637 | 320002208 | 1.66 | 80 | Neo-adjuvant (N) | 2016-09-25 | 2016-09-25 | Docetaxel | N | N | 320023541 | POUT TRIAL |
| 320003638 | 320002209 | 1.87 | 109 | null | 2016-05-23 | 2016-05-23 | Cisplatin + Gemcitabine (D 1 & 8) | null | null | 320023546 | DOCETAXEL |
| 320003639 | 320002210 | null | 82.3 | Neo-adjuvant (N) | 2015-11-07 | 2015-11-15 | ECX | null | N | 320023550 | CISPLATIN + FLUOROURACIL + RT |
| 320003640 | 320002210 | 1.65 | 75.4 | Palliative (P) | null | 2013-11-01 | CISPLATIN + GEMCITABINE | N | N | 320023550 | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL |
| 320003641 | 320002211 | 1.7 | 67.8 | Curative (C) | 2014-08-12 | 2014-08-19 | CARBOPLATIN + RT | 02 | N | 320023560 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320003642 | 320002211 | 1.61 | null | Curative (C) | null | 2014-05-27 | OCTREOTIDE | null | null | 320023560 | BEVACIZUMAB |
| 320003643 | 320002212 | 1.31 | 80.5 | Palliative (P) | 2013-07-28 | 2013-07-31 | Dacarbazine | 02 | N | 320023564 | GEMCITABINE |
| 320003644 | 320002213 | 1.72 | null | Curative (C) | 2015-03-22 | 2015-04-04 | CISPLATIN + DOCETAXEL + FLUOROURACIL | N | Y | 320023573 | COMPARE TRIAL |
| 320003645 | 320002213 | 1.64 | 45.2 | Adjuvant (A) | 2014-06-22 | 2014-06-22 | BEVACIZUMAB + CARBO + PACLITAXEL | N | N | 320023573 | VINCRISTINE |
| 320003646 | 320002213 | 0 | 95.8 | Curative (C) | 2017-07-27 | 2017-08-22 | Carbo + Liposomal Dox + Paclitaxel | N | Y | 320023573 | CETUXIMAB + RT |
| 320003647 | 320002213 | 1.72 | 59 | null | 2014-01-19 | 2014-09-27 | CISPLATIN + GEMCITABINE | N | N | 320023573 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320003648 | 320002214 | 1.93 | 71.2 | Palliative (P) | 2014-02-11 | 2015-01-22 | Trial Unspecified | 02 | N | 320023596 | CISPLATIN + ETOPOSIDE |
| 320003649 | 320002214 | null | null | Palliative (P) | 2018-01-22 | 2018-01-23 | BEVACIZUMAB + CARBO | N | N | 320023596 | CETUXIMAB + CISPLATIN + FU |
| 320003650 | 320002215 | 1.72 | null | Neo-adjuvant (N) | 2013-10-27 | 2013-10-29 | CETUXIMAB + RT | 02 | null | 320023599 | CETUXIMAB + RT |
| 320003651 | 320002216 | 1.65 | 85 | Adjuvant (A) | 2014-01-04 | 2014-01-12 | ECX | N | N | 320023600 | CISPLATIN + GEMCITABINE |
| 320003652 | 320002217 | 1.58 | 105.3 | Adjuvant (A) | 2016-04-20 | 2016-04-28 | Sorafenib | N | N | 320023603 | DOCETAXEL + GEMCITABINE |
| 320003653 | 320002218 | 1.7 | 90 | Palliative (P) | 2014-01-08 | 2014-01-25 | Cisplatin + Gemcitabine (D 1 & 8) | N | N | 320023607 | CABAZITAXEL |